Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRYX1P)

Drug Name

CEL-1000 Drug Info

Synonyms

CEL-1000C; DerG, CEL-SCI; Immunostimulant peptide, CEL-SCI; Peptide vaccine (Vaxcine, oral, herpes simplex virus infection); Peptide vaccine (Vaxcine, oral, herpes simplex virus infection), Infexion

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMRYX1P

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell surface glycoprotein CD4 (CD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibalizumab	DMV67QO	Human immunodeficiency virus infection	1C62	Approved	[2]
TNX-355	DMYA41S	Human immunodeficiency virus infection	1C62	Phase 3	[3]
Zanolimumab	DMKB4ZY	Lymphoma	2A80-2A86	Phase 3	[4]
Magrolimab	DMVXUR0	Acute myeloid leukaemia	2A60	Phase 3	[5]
Fluoropeptide vaccine	DMCEUOH	Influenza virus infection	1E30-1E32	Phase 2	[6]
BT-061	DM2LZIY	Asthma	CA23	Phase 2	[7]
LIPO-4	DMJRALD	Human immunodeficiency virus infection	1C62	Phase 1	[8]
Combinectin	DMTLP1N	Human immunodeficiency virus infection	1C62	Phase 1	[9]
TMB-365	DMH3E5C	Human immunodeficiency virus-1 infection	1C62	Phase 1	[10]
CD4CAR	DM09SW6	T-cell leukaemia	2A90	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD4 (CD4)	TTN2JFW	CD4_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother. 2004 Jul;48(7):2455-63.
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
4	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
5	Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
6	A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
7	Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
8	Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
9	Clinical pipeline report, company report or official report of ViiV Healthcare.
10	Clinical pipeline report, company report or official report of TaiMed Biologics.
11	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.